Results 21 to 30 of about 36,274 (199)

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

Cell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner, Teresita del N.J. Flores-Tellez, Renaud Mevel, Amin Ali, Pengbo Wang, Pieta Schofield, Caron Behan, Nicholas Forsythe, Garry Ashton, Catherine Taylor, Ian G. Mills, Pedro Oliveira, Simon S. McDade, Dietmar M. Zaiss, Ananya Choudhury, Georges Lacaud, Esther Baena   +16 more
doaj   +1 more source

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

Cell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva, Douglas E. Linn, Ivana Steiner, Guoji Guo, Adnan Ali, Hubert Pakula, Garry Ashton, Isabel Peset, Michael Brown, Noel W. Clarke, Roderick T. Bronson, Guo-Cheng Yuan, Stuart H. Orkin, Zhe Li, Esther Baena   +14 more
doaj   +1 more source

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

IJU Case Reports, 2022
Introduction Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established.
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya   +8 more
doaj   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Pharmaceutics, 2022
Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of non-
Dhruvitkumar S. Sutaria, Grozdana Rasuo, Adam Harris, Ryan Johnson, Dale Miles, Jorge Daniel Gallo, Rucha Sane   +6 more
doaj   +1 more source

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi, Oluwakemi Anuoluwapo Rotimi, Abdulkadir Ayo Salako, Paul Jibrin, Jelili Oyelade, Emeka E. J. Iweala   +5 more
doaj   +1 more source

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

BMC Urology, 2022
Background Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter ...
Yan Li, Hui Shi, Zhenjun Zhao, Minghui Xu   +3 more
doaj   +1 more source

Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer

Folia Medica Indonesiana, 2022
Highlight: • Assessing the survival rate in castration-resistant prostate cancer was descriptived. • PSA level between survivor and non survivor was significant but not for PSA nadir level, TTN and TTC.
Firmantya Hadi Pranata, Wahjoe Djatisoesanto, Doddy Moesbadianto Soebadi   +2 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer

Neoplasia: An International Journal for Oncology Research
The androgen receptor (AR) is a pivotal regulator of growth and survival of prostate cancer (PCa) and the majority of lethal castration-resistant prostate cancers (CRPC) remain reliant on AR signaling.
Maria Malvina Tsamouri, Stephen J. Libertini, Salma Siddiqui, Maitreyee K. Jathal, Blythe P. Durbin-Johnson, Clifford G. Tepper, Eva Corey, Jun Luo, Kenneth A. Iczkowski, Paramita M. Ghosh, Maria Mudryj   +10 more
doaj   +1 more source